New drug LTG-001 enters first human safety tests
Knowledge-focused
Ongoing
This early-stage study is testing a new drug, LTG-001, in 204 healthy adults aged 18 to 55. The goal is to check how safe the drug is, how well people tolerate it, and how it moves through the body. Participants will receive either the drug or a placebo by mouth or through a vein…
Phase: PHASE1 • Sponsor: Latigo Biotherapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC